Pablo A. Fraile-Ribot

Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

Pablo A. Fraile-Ribot, Gabriel Cabot, Xavier Mulet et al. · Journal of Antimicrobial Chemotherapy · 2017 · 203 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Pablo A. Fraile-Ribot, Laura Zamorano, Rocío Orellana et al. · Antimicrobial Agents and Chemotherapy · 2019 · 83 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands

Manuel Díaz Cañestro, Leonor Periañez, Xavier Mulet et al. · European Journal of Clinical Microbiology & Infectious Diseases · 2018 · 74 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

<i>In Vivo</i> Emergence of Resistance to Novel Cephalosporin–β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa

Pablo A. Fraile-Ribot, Xavier Mulet, Gabriel Cabot et al. · Antimicrobial Agents and Chemotherapy · 2017 · 71 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +12

Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant <i>Pseudomonas aeruginosa</i>

Cristina Lasarte-Monterrubio, Pablo A. Fraile-Ribot, Juan Carlos Vázquez-Ucha et al. · Journal of Antimicrobial Chemotherapy · 2022 · 53 citations

Life Sciences, Infectious Diseases, Microbiology +17